Product information:
| Product name |
Clindamycin Hydrochloride for Injection |
| Specifications |
150mg/450mg/600mg |
| Package |
Customizable |
| Storage |
Cool & Dry Place |
| Shelf Life |
2 Years |
Indication:
Gram positive bacteria cause the following infectious diseases:
1. Tonsillitis, suppurative otitis media, sinusitis, etc.
2. Acute bronchitis, acute attack of chronic bronchitis, pneumonia, lung abscess and bronchiectasis with infection, etc.
3. Skin and soft tissue infection; furuncle, carbuncle, abscess, cellulitis, wound, burn and surgical infection.
4. Urinary tract infection, acute urethritis, acute pyelonephritis, prostatitis, etc.
5. Others: osteomyelitis, sepsis, peritonitis and oral infection.
Various infectious diseases caused by anaerobic bacteria:
1. Empyema, muscle abscess, anaerobic pneumonia.
2. Skin and soft tissue infection, sepsis.
3. Intra abdominal infection: peritonitis, intra-abdominal abscess.
4. Female pelvic and genital infection: endometritis, non gonococcal oviduct and ovarian abscess, pelvic cellulitis and infection after gynecological operation.
Usage and dosage:
Adult: deep intramuscular injection or intravenous drip.
Moderate infection: 0.6-1.2g/day, 2-3 times.
Severe infection: 1.2-2.7g/day, 2-3 times. Or follow the doctor's advice.
Children: intramuscular or intravenous administration
Moderate infection: 15-25mg / kg / day, 2-3 times.
Severe infection: 25-40 mg / kg / day, 2-3 times or as directed by the doctor.
Intravenous drip: dilute 0.3g of the product with 100ml normal saline or 5% glucose solution for 30 minutes.
Adverse reactions:
1. Gastrointestinal reactions: common nausea, vomiting, abdominal pain, diarrhea, etc.; severe cases include abdominal colic, abdominal tenderness, severe diarrhea (watery or pus like), accompanied by fever, abnormal thirst and fatigue (pseudomembranous enteritis). Diarrhea, enteritis and pseudomembranous enteritis may occur at the beginning of the treatment, or a few weeks after discontinuation.
2. Blood system: leucopenia, neutropenia, eosinophilia and thrombocytopenia are occasionally seen; aplastic anemia is rare.
3. Allergic reaction: rash, pruritus, urticaria, vascular edema and serological reaction are seen occasionally. Exfoliative dermatitis, bullous dermatitis, erythema multiforme and Steven Johnson syndrome are rare.
4. Abnormal liver and kidney functions, such as elevated serum aminotransferase, jaundice, etc.
5. Intravenous drip may cause phlebitis; intramuscular injection may cause local pain, induration and aseptic abscess.
6. Others: tinnitus, vertigo, Candida infection, etc.
Matters needing attention:
1. This product has no cross allergic reaction with penicillin and cephalosporin antibiotics, and can be used for those allergic to penicillin. Those with a history of asthma or other allergies should be cautious, which may lead to aggravation of asthma.
2. When using, please strictly abide by the usage and dosage of the drug instructions, and pay attention to the infusion speed and fractional administration. When the dosage of intravenous administration is too large, the infusion speed is too fast, and the concentration is too high, this product may lead to renal function damage, hematuria, and renal failure in severe cases.
3. This product has incompatibility with ampicillin, phenytoin, barbital hydrochloride, aminophylline, calcium gluconate and magnesium sulfate; it has antagonistic effect with erythromycin and should not be used in combination.
4. Patients with liver and kidney dysfunction and children under 4 years old should be cautious. Pregnant women and lactating women should weigh the advantages and disadvantages when using this product.
5. In case of pseudomembranous enteritis, vancomycin 0.125-0.5g was taken orally, 4 times a day.
6. The results of animal muscle irritation test showed that this product could cause severe congestion and muscle degeneration in quadriceps femoris of rabbits after intramuscular injection.
Pharmacology and Toxicology
Pharmacological action:
This product is a kind of lincoamide antibiotic. It can inhibit the early protein synthesis of bacteria by binding with the ribosome of 50S subunit bacteria, remove the a protein and villous coat on the surface of bacteria, and make it easy to be swallowed and killed. In vitro experiments showed that clindamycin was active against the following microorganisms
1. Aerobic gram positive cocci: Staphylococcus aureus and Staphylococcus epidermidis (including penicillinase producing and non penicillinase producing strains), Streptococcus (except Enterococcus faecalis) and pneumococcus.
2. Anaerobic gram negative bacilli: Bacteroides (including vulnerable Bacteroides and melanogenic Bacteroides) and fusobacteria.
3. Anaerobic gram positive non producing Bacillus: Propionibacterium, Eubacterium and actinomycetes.
4. Anaerobic and microaerobic gram positive bacilli: peptococcus, microaerobic Streptococcus and peptococcus.
Toxicological studies:
Genotoxicity: Ames Salmonella reverse mutation test and rat micronucleus test were negative.
Reproductive toxicity: the dose of 300 mg / kg was given orally to rats, and there was no effect on animal mating and fertility. Rats and mice were given clindamycin 600 mg / kg orally or 250 mg / kg subcutaneously, respectively, and no teratogenic effect was found. However, there is no sufficient and strict clinical research on pregnant women. Animal reproductive research can not fully predict human response. Only when it is clearly needed, can this product be used during pregnancy.
Audited Supplier 
){kind=link}